Compile Data Set for Download or QSAR
Report error Found 410 Enz. Inhib. hit(s) with all data for entry = 10475
TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538275(US11254663, Example 117)
Affinity DataEC50:  12nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538598(US11254663, Example 543)
Affinity DataEC50:  14nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538277(US11254663, Example 119)
Affinity DataEC50:  15nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538278(US11254663, Example 120)
Affinity DataEC50:  15nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538400(US11254663, Example 308)
Affinity DataEC50:  15nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538524(US11254663, Example 452)
Affinity DataEC50:  17nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538527(US11254663, Example 455)
Affinity DataEC50:  17nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538266(US11254663, Example 107)
Affinity DataEC50:  18nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538374(US11254663, Example 282)
Affinity DataEC50:  19nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538599(US11254663, Example 544)
Affinity DataEC50:  20nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538321(US11254663, Example 195)
Affinity DataEC50:  20nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538597(US11254663, Example 542)
Affinity DataEC50:  22nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538279(US11254663, Example 121)
Affinity DataEC50:  22nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538363(US11254663, Example 271)
Affinity DataEC50:  23nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538309(US11254663, Example 176)
Affinity DataEC50:  24nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538417(US11254663, Example 325)
Affinity DataEC50:  24nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538505(US11254663, Example 431)
Affinity DataEC50:  25nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538427(US11254663, Example 335)
Affinity DataEC50:  26nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538589(US11254663, Example 533)
Affinity DataEC50:  26nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538280(US11254663, Example 122)
Affinity DataEC50:  28nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538592(US11254663, Example 536)
Affinity DataEC50:  29nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538276(US11254663, Example 118)
Affinity DataEC50:  30nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538526(US11254663, Example 454)
Affinity DataEC50:  31nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538458(US11254663, Example 376)
Affinity DataEC50:  32nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538525(US11254663, Example 453)
Affinity DataEC50:  34nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538273(US11254663, Example 115)
Affinity DataEC50:  35nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538369(US11254663, Example 277)
Affinity DataEC50:  35nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538482(US11254663, Example 402)
Affinity DataEC50:  35nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538466(US11254663, Example 385)
Affinity DataEC50:  35nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538507(US11254663, Example 433)
Affinity DataEC50:  37nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538235(US11254663, Example 58)
Affinity DataEC50:  39nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538504(US11254663, Example 430)
Affinity DataEC50:  40nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538463(US11254663, Example 381)
Affinity DataEC50:  40nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538481(US11254663, Example 401)
Affinity DataEC50:  42nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538299(US11254663, Example 157)
Affinity DataEC50:  43nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538300(US11254663, Example 160)
Affinity DataEC50:  43nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538454(US11254663, Example 371)
Affinity DataEC50:  45nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538359(US11254663, Example 267)
Affinity DataEC50:  46nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538511(US11254663, Example 438)
Affinity DataEC50:  46nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538510(US11254663, Example 436)
Affinity DataEC50:  46nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538468(US11254663, Example 387)
Affinity DataEC50:  47nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538523(US11254663, Example 451)
Affinity DataEC50:  47nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538254(US11254663, Example 89)
Affinity DataEC50:  47nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538600(US11254663, Example 546)
Affinity DataEC50:  48nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538381(US11254663, Example 289)
Affinity DataEC50:  48nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538354(US11254663, Example 261)
Affinity DataEC50:  48nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538474(US11254663, Example 393)
Affinity DataEC50:  49nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538506(US11254663, Example 432)
Affinity DataEC50:  51nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538480(US11254663, Example 400)
Affinity DataEC50:  51nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

TargetBile acid receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM538459(US11254663, Example 377)
Affinity DataEC50:  52nMAssay Description:A Gal4-hFXR fusion construct reporter system was used as the primary assay to characterize compound activity. A construct including 5 copies of the G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2022
Entry Details
US Patent

Displayed 1 to 50 (of 410 total ) | Next | Last >>
Jump to: